Skip to main content
. 2022 Mar 9;14(6):1390. doi: 10.3390/cancers14061390
AKT, Akt protein kinase B
AMPK adenosine monophosphate-activated protein kinase
ATP adenosine 5′-triphosphate
cAMP-PKA cyclic adenosine monophosphate protein kinase A
CLP common lymphoid progenitor
CP cyclophosphamide
CR complete response
CT chemotherapy
DC dendritic cells
DSR differential stress resistance
DXR doxorubicin
ECM extracellular matrix
EGR1 early growth response 1
FMD fasting mimicking diet
G-CSF granulocyte colony-stimulating factor
HER2 human epidermal growth factor receptor 2
HO-1 heme oxygenase-1
HR+ hormone receptor positive
ICD immunogenic cell death
IFNγ interferon gamma
IGF-1 insulin growth factor 1
IGF1R insulin growth factor 1 receptor
M-CSF macrophage colony-stimulating factor
MDSC myeloid derived suppressor cells
mTOR mammalian target of rapamycin
MTX mitoxantrone
NK natural killer cell
OX oxaliplatin
PBMC peripheral blood mononuclear cell
PD1 programmed cell death protein 1
PD-L1 programmed cell death protein 1 ligand
PI3K phosphoinositide 3-kinase
PR partial response
QoL quality of life
ROS reactive oxygen species
RT radiation therapy
STF short-term fasting
TAC docetaxel/doxorubicin/cyclophosphamide
TAM tumor associated macrophages
TIL tumor infiltrating lymphocyte
Tregs regulatory T cells